Skip to main content

Viibryd FDA Approval History

FDA Approved: Yes (First approved January 21, 2011)
Brand name: Viibryd
Generic name: vilazodone
Dosage form: Tablets
Company: Allergan plc
Treatment for: Depression

Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).

Development timeline for Viibryd

DateArticle
Mar 16, 2015Approval Actavis Receives FDA Approval for Viibryd (vilazodone HCl) 20mg Once Daily as a Therapeutic Dose
Jan 24, 2011Approval FDA Approves Viibryd to Treat Major Depressive Disorder
Nov 16, 2010Clinical Data, Inc. Announces Issuance of New U.S. Patent for Vilazodone
May 24, 2010Clinical Data, Inc. Announces FDA Acceptance of New Drug Application for Vilazodone for the Treatment of Major Depressive Disorder
Mar 23, 2010Clinical Data Submits NDA for Depression Compound

See also

Viibryd (vilazodone) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer